Nanobiotechnology in drug delivery

American Journal of Drug Delivery

Volumn 4, Issue 2, 2006, Pages 79-88

  Azad, Neelam ^a   Rojanasakul, Yon ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; COPOLYMER; CYANOACRYLATE DERIVATIVE; DEXAMETHASONE; DICLOFENAC; DOXORUBICIN; ENFUVIRTIDE; GANCICLOVIR; INDOMETACIN; INSULIN; LEUPRORELIN; LIPOSOME; MACROGOL; NANOCAPSULE; NANOPARTICLE; PARATHYROID HORMONE[1-34]; POLY(3 HYDROXYBUTYRIC ACID); POLYLACTIDE; POLYMER; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN; VACCINE; VIRUS VECTOR;

BIOTECHNOLOGY; CANCER; CANCER CHEMOTHERAPY; DNA TRANSFECTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SPECIFICITY; DRUG TARGETING; ENDOCYTOSIS; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MICELLE; NANOTECHNOLOGY; NONHUMAN; OSTEOPOROSIS; OVARY CANCER; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; REVIEW;

EID: 33745889941     PISSN: 11759038     EISSN: 11759038     Source Type: Journal    
DOI: 10.2165/00137696-200604020-00003     Document Type: Review

References (111)

1. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003; 8 (24): 1112-20
2. Saltzman M, Desai T. Drug delivery in the BME curricula. Ann Biomed Eng 2006; 34 (2): 270-5
3. Orive G, Hernandez RM, Rodriguez Gascon A, et al. Drug delivery in biotechnology: present and future. Curr Opin Biotechnol 2003; 14 (6): 659-64
4. Yokoyama M. Drug targeting with nano-sized carrier systems. J Artif Organs 2005; 8 (2): 77-84
5. Ernest H, Shetty R. Impact of nanotechnology on biomedical sciences: review of current concepts on convergence of nanotechnology with biology. AZojono J Nanotechnol Online 2005; 1: 1-14
6. Hughes GA. Nanostructure-mediated drug delivery. Dis Mon 2005; 51 (6): 342-61
7. Litzinger DC, Buiting AM, van Rooijen N, et al. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly (ethylene glycol)-containing liposomes. Biochim Biophys Acta 1994; 1190 (1): 99-107
8. Kefalides PT. New methods for drug delivery. Ann Intern Med 1998; 128 (12 Pt 1): 1053-5
9. Peppas NA. Intelligent therapeutics: biomimetic systems and nanotechnology in drug delivery. Adv Drug Deliv Rev 2004; 56 (11): 1529-31
10. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001; 53 (2): 283-318
11. Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51 (4): 691-743
12. Martin CR, Kohli P. The emerging field of nanotube biotechnology. Nat Rev Drug Discov 2003; 2 (1): 29-37
13. Svenson S, Tomalia DA. Dendrimers in biomedical applications: reflections on the field. Adv Drug Deliv Rev 2005; 57 (15): 2106-29
14. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 2005; 57 (15): 2215-37
15. Kohli P, Martin CR. Smart nanotubes for biomedical and biotechnological applications. Drug News Perspect 2003; 16 (9): 566-73
16. Torchilin VP. Lipid-core micelles for targeted drug delivery. Curr Drug Deliv 2005; 2 (4): 319-27
17. Rosler A, Vandermeulen GW, Klok HA. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev 2001; 53 (1): 95-108
18. Sarker DK. Engineering of nanoemulsions for drug delivery. Curr Drug Deliv 2005; 2 (4): 297-310
19. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54 (5): 631-51
20. Desai MP, Labhasetwar V, Amidon GL, et al. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996; 13 (12): 1838-45
21. Panyam J, Sahoo SK, Prabha S, et al. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly (D,L-lactide-co-glycolide) nanoparticles. Int J Pharm 2003; 262 (1-2): 1-11
22. Jilek S, Merkle HP, Walter E. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev 2005; 57 (3): 377-90
23. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003; 55 (3): 329-47
24. O'Hagan DT. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord 2001; 1 (3): 273-86
25. Webster DEG, Strugnell RA, Wesselingh SL. Advances in oral vaccine delivery options: What is on the horizon? Am J Drug Deliv 2003; 1 (4): 227-40
26. Lin JH, Weng CN, Liao CW, et al. Protective effects of oral microencapsulated Mycoplasma hyopneumoniae vaccine prepared by co-spray drying method. J Vet Med Sci 2003; 65 (1): 69-74
27. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials 2000; 21 (23): 2475-90
28. Langer R. Tissue engineering: a new field and its challenges. Pharm Res 1997; 14 (7): 840-1
29. Lin SY, Chen KS, Teng HH, et al. In vitro degradation and dissolution behaviours of microspheres prepared by three low molecular weight polyesters. J Microencapsul 2000; 17 (5): 577-86
30. Jones AJ, Putney S, Johnson OL, et al. Recombinant human growth hormone poly (lactic-co-glycolic acid) microsphere formulation development. Adv Drug Deliv Rev 1997; 28 (1): 71-84
31. Lutsiak ME, Robinson DR, Coester C, et al. Analysis of poly (D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 2002; 19 (10): 1480-7
32. Panyam J, Labhasetwar V. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm 2004; 1 (1): 77-84
33. Piddubnyak V, Kurcok P, Matuszowicz A, et al. Oligo-3-hydroxybutyrates as potential carriers for drug delivery. Biomaterials 2004; 25 (22): 5271-9
34. Salgueiro A, Gamisans F, Espina M, et al. Cyclophosphamide-loaded nanospheres: analysis of the matrix structure by thermal and spectroscopic methods. J Microencapsul 2002; 19 (3): 305-10
35. Kumar R, Chen MH, Parmar VS, et al. Supramolecular assemblies based on copolymers of PEG600 and functionalized aromatic diesters for drug delivery applications. J Am Chem Soc 2004; 126 (34): 10640-4
36. Van Domeselaar GH, Andrew LC. Application of solid phase peptide synthesis to engineering PEOpeptide block copolymers for drug delivery. Colloids Surf B Biointerfaces 2003; 30: 323-34
37. Luu YK, Kim K, Hsiao BS, et al. Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA-PEG block copolymers. J Control Release 2003; 89 (2): 341-53
38. Vila A, Gill H, McCallion O, et al. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J Control Release 2004; 98 (2): 231-44
39. Li YY, Cunin F, Link JR, et al. Polymer replicas of photonic porous silicon for sensing and drug delivery applications. Science 2003; 299 (5615): 2045-7
40. Lu Y, Chen SC. Micro and nano-fabrication of biodegradable polymers for drug delivery. Adv Drug Deliv Rev 2004; 56 (11): 1621-33
41. Dalby MJ, Berry CC, Riehle MO, et al. Attempted endocytosis of nano-environment produced by colloidal lithography by human fibroblasts. Exp Cell Res 2004; 295 (2): 387-94
42. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2 (5): 347-60
43. Dokka S, Rojanasakul Y. Novel non-endocytic delivery of antisense oligonucleotides. Adv Drug Deliv Rev 2000; 44 (1): 35-49
44. Akhtar S, Hughes MD, Khan A, et al. The delivery of antisense therapeutics. Adv Drug Deliv Rev 2000; 44 (1): 3-21
45. Greish K, Fang J, Inutsuka T, et al. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 2003; 42 (13): 1089-105
46. Cao A, Briane D, Coudert R, et al. Delivery and pathway in MCF7 cells of DNA vectorized by cationic liposomes derived from cholesterol. Antisense Nucleic Acid Drug Dev 2000; 10 (5): 369-80
47. Mahato RI, Takakura Y, Hashida M. Development of targeted delivery systems for nucleic acid drugs. J Drug Target 1997; 4 (6): 337-57
48. Leonetti JP, Mechti N, Degols G, et al. Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci U S A 1991; 88 (7): 2702-6
49. Renneisen K, Leserman L, Matthes E, et al. Inhibition of expression of human immunodeficiency virus-1 in vitro by antibody-targeted liposomes containing antisense RNA to the env region. J Biol Chem 1990; 265 (27): 16337-42
50. Dass CR. Biochemical and biophysical characteristics of lipoplexes pertinent to solid tumour gene therapy. Int J Pharm 2002; 241 (1): 1-25
51. Kamps JA, Morselt HW, Scherphof GL. Uptake of liposomes containing phosphatidylserine by liver cells in vivo and by sinusoidal liver cells in primary culture: in vivo-in vitro differences. Biochem Biophys Res Commun 1999; 256 (1): 57-62
52. Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987; 3 (2): 123-93
53. Allen TM, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 1987; 223 (1): 42-6
54. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19 (4): 424-36
55. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13 (7): 1777-85
56. Miyazaki S, Takahashi A, Kubo W, et al. Poly n-butylcyanoacrylate (PNBCA) nanocapsules as a carrier for NSAIDs: in vitro release and in vivo skin penetration. J Pharm Sci 2003; 6 (2): 238-45
57. Couvreur P, Barratt G, Fattal E, et al. Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst 2002; 19 (2): 99-134
58. Mayer C. Nanocapsules as drug delivery systems. Int J Artif Organs 2005; 28 (11): 1163-71
59. Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 2001; 47 (1): 55-64
60. Aprahamian M, Michel C, Humbert W, et al. Transmucosal passage of poly-alkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol Cell 1987; 61 (1-2): 69-76
61. Damge CA, Balboni G, Hoeltzel A, et al. Polyalkylcyanoacrylate nanocapsules increase the intestinal absorption of a lipophilic drug. Int J Pharm 1987; 36: 121-5
62. Ammoury N, Fessi H, Devissaguet JP, et al. Jejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly (d,l-lactide) and poly (isobutyl-cyanoacrylate) nanocapsules in rats. Pharm Res 1991; 8 (1): 101-5
63. Damge C, Michel C, Aprahamian M, et al. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 1988; 37 (2): 246-51
64. Guterres SS, Fessi H, Barratt G, et al. Poly (rac-lactide) nanocapsules containing diclofenac: protection against muscular damage in rats. J Biomater Sci Polym Ed 2000; 11 (12): 1347-55
65. Torchilin VP, Khaw BA, Weissig V. Intracellular targets for DNA delivery: nuclei and mitochondria. Somat Cell Mol Genet 2002; 27 (1-6): 49-64
66. Nori A, Kopecek J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev 2005; 57 (4): 609-36
67. Belting M, Sandgren S, Wittrup A. Nuclear delivery of macromolecules: barriers and carriers. Adv Drug Deliv Rev 2005; 57 (4): 505-27
68. Dass CR. Oligonucleotide delivery to tumours using macromolecular carriers. Biotechnol Appl Biochem 2004; 40 (Pt 2): 113-22
69. Gansbacher B. Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT). J Gene Med 2003; 5 (3): 261-2
70. Lee M, Kim SW. Polyethylene glycol-conjugated copolymers for plasmid DNA delivery. Pharm Res 2005; 22 (1): 1-10
71. Pitard B. Supramolecular assemblies of DNA delivery systems. Somat Cell Mol Genet 2002; 27 (1-6): 5-15
72. Carmo-Fonseca M. The contribution of nuclear compartmentalization to gene regulation. Cell 2002; 108 (4): 513-21
73. Coonrod A, Li FQ, Horwitz M. On the mechanism of DNA transfection: efficient gene transfer without viruses. Gene Ther 1997; 4 (12): 1313-21
74. Duzgunes N, De Ilarduya CT, Simoes S, et al. Cationic liposomes for gene delivery: novel cationic lipids and enhancement by proteins and peptides. Curr Med Chem 2003; 10 (14): 1213-20
75. Liu D, Ren T, Gao X. Cationic transfection lipids. Curr Med Chem 2003; 10 (14): 1307-15
76. Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002; 54 (5): 715-58
77. Sandgren S, Wittrup A, Cheng F, et al. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J Biol Chem 2004; 279 (17): 17951-6
78. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000; 18 (1): 33-7
79. Wiethoff CM, Middaugh CR. Barriers to nonviral gene delivery. J Pharm Sci 2003; 92 (2): 203-17
80. Dauty E, Remy JS, Zuber G, et al. Intracellular delivery of nanometric DNA particles via the folate receptor. Bioconjug Chem 2002; 13 (4): 831-9
81. Qian ZM, Li H, Sun H, et al. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002; 54 (4): 561-87
82. Wu CH, Wilson JM, Wu GY. Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo. J Biol Chem 1989; 264 (29): 16985-7
83. Zanta MA, Belguise-Valladier P, Behr JP. Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci U S A 1999; 96 (1): 91-6
84. Cryan SA. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J 2005; 7 (1): E20-41
85. Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 2003; 8 (6): 259-66
86. Takakura Y, Hashida M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm Res 1996; 13 (6): 820-31
87. Bai JP, Chang LL. Comparison of site-dependent degradation of peptide drugs within the gut of rats and rabbits. J Pharm Pharmacol 1993; 45 (12): 1085-7
88. Gombotz WR, Pettit DK. Biodegradable polymers for protein and peptide drug delivery. Bioconjug Chem 1995; 6 (4): 332-51
89. Zelphati O, Wang Y, Kitada S, et al. Intracellular delivery of proteins with a new lipid-mediated delivery system. J Biol Chem 2001; 276 (37): 35103-10
90. Tinsley JH, Hawker J, Yuan Y. Efficient protein transfection of cultured coronary venular endothelial cells. Am J Physiol 1998; 275 (5 Pt 2): H1873-8
91. van de Weert M, Hoechstetter J, Hennink WE, et al. The effect of a water/organic solvent interface on the structural stability of lysozyme. J Control Release 2000; 68 (3): 351-9
92. Zhu G, Mallery SR, Schwendeman SP. Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide). Nat Biotechnol 2000; 18 (1): 52-7
93. Mathiowitz E, Jacob JS, Jong YS, et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 1997; 386 (6623): 410-4
94. Leone-Bay A, Ho KK, Agarwal R, et al. 4-[4-[(2-Hydroxybenzoyl)amino] phenyl]butyric acid as a novel oral delivery agent for recombinant human growth hormone. J Med Chem 1996; 39 (13): 2571-8
95. Milstein SJ, Leipold H, Sarubbi D, et al. Partially unfolded proteins efficiently penetrate cell membranes: implications for oral drug delivery. J Control Release 1998; 53 (1-3): 259-67
96. Cho MJ, Juliano R. Macromolecular versus small-molecule therapeutics: drug discovery, development and clinical considerations. Trends Biotechnol 1996; 14 (5): 153-8
97. Azad N, Rojanasakul Y. Vaccine delivery: current trends and future. Curr Drug Deliv 2006; 3 (2): 137-46
98. McCluskie MJ, Weeratna RD. Novel adjuvant systems. Curr Drug Targets Infect Disord 2001; 1 (3): 263-71
99. Payette PJ, Davis HL. History of vaccines and positioning of current trends. Curr Drug Targets Infect Disord 2001; 1 (3): 241-7
100. Glenny AT, Pope CG, Waddington H, et al. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926; 29: 31-40
101. O'Hagan DT, MacKichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 2001; 18 (3): 69-85
102. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292 (5514): 69-74
103. Ambrosch F, Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15 (11): 1209-13
104. Davis HL, Schirmbeck R, Reimann J, et al. DNA-mediated immunization in mice induces a potent MHC class I-restricted cytotoxic T lymphocyte response to the hepatitis B envelope protein. Hum Gene Ther 1995; 6 (11): 1447-56
105. Davis HL, Weeratna R, Waldschmidt TJ, et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998; 160 (2): 870-6
106. Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharm Biotechnol 1995; 6: 141-228
107. Alpar HO, Bramwell VW. Current status of DNA vaccines and their route of administration. Crit Rev Ther Drug Carrier Syst 2002; 19 (4-5): 307-83
108. Jung T, Kamm W, Breitenbach A, et al. Tetanus toxoid loaded nanoparticles from sulfobutylated poly (vinyl alcohol)-graft-poly (lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm Res 2001; 18 (3): 352-60
109. Raghuvanshi RJ, Mistra A, Talwar GP, et al. Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid. J Microencapsul 2001; 18 (6): 723-32
110. Kreuter J, Speiser PP. In vitro studies of poly (methyl methacrylate) adjuvants. J Pharm Sci 1976; 65 (11): 1624-7
111. Desai MP, Hilfinger JM, Amidon GL, et al. Immune response with biodegradable nanospheres and alum: studies in rabbits using staphylococcal enterotoxin B-toxoid. J Microencapsul 2000; 17 (2): 215-25